American Journal of Obstetrics & Gynecology
Volume 200, Issue 3 , Pages 329.e1-329.e8 , March 2009

Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use

Presented at the 75th Annual Meeting of the Central Association of Obstetricians and Gynecologists, New Orleans, LA, Oct. 22-25, 2008.

  • Abbey B. Berenson, MD

      Affiliations

    • Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, TX
    • Center for Interdisciplinary Research in Women's Health, The University of Texas Medical Branch, Galveston, TX
    • Corresponding Author InformationReprints: Abbey B. Berenson, MD, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555-0587
    • ,
  • Mahbubur Rahman, MBBS, PhD, MPH

      Affiliations

    • Center for Interdisciplinary Research in Women's Health, The University of Texas Medical Branch, Galveston, TX

Received 30 June 2008 ,Revised 15 November 2008 ,Accepted 29 December 2008.

References 

  1. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception. 2006;74:90–99
  2. Polaneczky M, Liblanc M. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents. J Adolesc Health. 1998;23:81–88
  3. Templeman C, Boyd H, Hertweck SP. Depomedroxyprogesterone acetate use and weight gain among adolescents. J Pediatr Adolesc Gynecol. 2000;13:45–46
  4. Bahamondes L, Del Castillo S, Tabares G, Arce XE, Perrotti M, Petta C. Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 years. Contraception. 2001;64:223–225
  5. Clark MK, Dillon JS, Sowers M, Nichols S. Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception. Int J Obes (Lond). 2005;29:1252–1258
  6. Mia AR, Siddiqui NI, Islam MN, Khan MR, Shampa SS, Rukunuzzaman M. Effects of prolonged use of injectable hormonal contraceptive on serum lipid profile. Mymensingh Med J. 2005;14:19–21
  7. Taneepanichskul S, Reinprayoon D, Khaosadad P. Comparative study of weight change between long-term DMPA and IUD acceptors. Contraception. 1998;58:149–151
  8. Tuchman LK, Huppert JS, Huang B, Slap GB. Adolescent use of the monthly contraceptive injection. J Pediatr Adolesc Gynecol. 2005;18:255–260
  9. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2002;15:79–82
  10. Espey E, Steinhart J, Ogburn T, Qualls C. Depo-Provera associated with weight gain in Navajo women. Contraception. 2000;62:55–58
  11. Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception. 1995;52:215–219
  12. Mukherjea M, Mukherjee P, Biswas R. Long-term contraception with Depo-Provera: a clinical evaluation. Int J Fertil. 1980;25:122–126
  13. Coney P, Washenik K, Langley RGB, DiGiovanna JJ, Harrison DD. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception. 2001;63:297–302
  14. de Melo NR, Aldrighi JM, Faggion D, et al. A prospective open-label study to evaluate the effects of the oral contraceptive Harmonet (gestodene75/EE20) on body fat. Contraception. 2004;70:65–71
  15. Lloyd T, Beck TJ, Lin HM, et al. Modifiable determinants of bone status in young women. Bone. 2002;30:416–421
  16. O'Connell KJ, Osborne LM, Westhoff C. Measured and reported weight change for women using a vaginal contraceptive ring vs a low-dose oral contraceptive. Contraception. 2005;72:323–327
  17. Berenson AB, Rahman M, Radecki Breitkopf C, Bi LX. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet Gynecol. 2008;112:788–789
  18. Litaker MS, Barbeau P, Humphries MC, Gutin B. Comparison of Hologic QDR-1000/W and 4500W DXA scanners in 13- to 18-year olds. Obesity Res. 2003;11:1545–1552
  19. Novotny R, Daida YG, Grove JS, Le Marchand L, Vijayadeva V. Asian adolescents have a higher trunk:peripheral fat ratio than Whites. J Nutr. 2006;136:642–647
  20. Schakel SF, Sievert YA, Buzzard IM. Sources of data for developing and maintaining a nutrient database. J Am Diet Assoc. 1988;88:1268–1271
  21. World Health Organization. Smoking QuestionnaireMONICA Manual (1998-1999), part III, section 1: the WHO MONICA (multinational monitoring trends in cardiovascular disease) project. MONICA Manual (1998-1999), part III, section 1: the WHO MONICA (multinational monitoring trends in cardiovascular disease) project. Geneva, Switzerland: WHO; 1999;
  22. National Cancer Institute. Diet history questionnaire (DHQ). Bethesda (MD): National Institutes of Health; 2000;
  23. Liang K, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13–22
  24. Schwallie PC, Assenzo JR. Contraceptive use: efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril. 1973;24:331–339
  25. Grueso E, Rocha M, Puerta M. Plasma and cerebrospinal fluid leptin levels are maintained despite enhanced food intake in progesterone-treated rats. Eur J Endocrinol. 2001;144:659–665
  26. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord. 2000;24:226–231
  27. Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and nonobese girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med. 2006;160:40–45

 Cite this article as: Berenson AB, Rahman M. Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. Am J Obstet Gynecol 2009;200:329.e1-329.e8.

 Supported by the National Institute of Child Health and Human Development Grants R01HD39883 and K24HD043659 (A.B.B.) and General Clinical Research Centers (GCRC) program, National Center for Research Resources, NIH, M01RR000073.

PII: S0002-9378(08)02460-5

doi: 10.1016/j.ajog.2008.12.052

American Journal of Obstetrics & Gynecology
Volume 200, Issue 3 , Pages 329.e1-329.e8 , March 2009

Article Tools

* Image Usage & Resolution